The rest of the 100 (in alphabetical order): Philippe Durieux has been acting chief executive of Vives Louvain Technology Fund
Philippe Durieux has been acting chief executive of Vives Louvain Technology Fund, the university venture fund of Université catholique de Louvain (UCL), since 2006.
He has held the same position at UCL’s tech transfer office Sopartec, which manages the Vives funds, during the same period.
Vives I was launched in 2004 with €15m ($17.5m), while Vives II was established in 2011 with €43m – making it the largest university venture fund in Europe at the time.
Since March 2013, Durieux has also been on the investment committee of French regional tech transfer office Satt Nord. Durieux was senior investment manager at Dexia Private Equity, the private equity division of financial services firm Dexia Bank Belgium, between 2002 and 2006.
Vives backs UCL companies. One of its spinouts, immunotherapy developer iTeos Therapeutics, raised $74m in series B funding led by Vives in June this year – one of the biggest deals for a biopharmaceutical startup in Europe.
